DURHAM, N.C. - Precision BioSciences, Inc. (NASDAQ:DTIL) has presented preclinical data at the European Society of Gene & Cell Therapy Congress in Rome, showcasing the high-efficiency gene editing capabilities of its ARCUS platform. The data, revealed on Thursday, indicates that ARCUS can perform sophisticated gene edits, such as insertions and replacements, with notable efficiency.
The ARCUS platform's potential extends beyond current gene editing methods, particularly for diseases needing functional restoration. Jeff Smith, PhD, Co-Founder and Chief Research Officer, highlighted that ARCUS achieves diverse gene editing outcomes through homology-directed repair (HDR), which is less common in gene editing enzymes. The preclinical study showed over 85% efficiency in T cells and 39% in primary human hepatocytes.
Unlike other gene editing tools limited to specific base changes or gene alterations, ARCUS can produce all twelve possible base changes and enable whole gene insertions or replacements. The unique enzymology of ARCUS nucleases, including a distinctive 4 base pair overhang cut, drives its high HDR rates, which could be harnessed for precise therapeutic gene editing.
Precision BioSciences aims to utilize ARCUS for in vivo gene editing therapies, targeting a broad range of genetic and infectious diseases where current treatments are inadequate. The company's approach differs in the way ARCUS nucleases cut DNA, their size, and simplicity, which may lead to more defined therapeutic outcomes.
The press release also contains forward-looking statements regarding the expected safety, efficacy, and clinical development of Precision BioSciences' product candidates, emphasizing the company's commitment to advancing its ARCUS technology in the gene editing field. However, as with all forward-looking statements, they are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected.
This information is based on a press release statement from Precision BioSciences, Inc.
In other recent news, Precision BioSciences has initiated a Phase 1 clinical trial for PBGENE-HBV, a potential cure for chronic hepatitis B, with the trial gaining approval in Moldova and applications pending in other regions. The company has also reshuffled its clinical leadership team with Dr. Murray Abramson appointed as Senior Vice President, Head of Clinical Development, and John Fry named as Strategic Clinical Advisor. These changes aim to advance the company's gene editing therapies. Additionally, Precision BioSciences has received a $13 million convertible note payment from Imugene Limited, bolstering its financial resources.
In partnership news, the company's collaborator, iECURE, received FDA Fast Track designation for its gene therapy candidate ECUR-506. Precision BioSciences has also submitted additional Clinical Trial Applications as part of its global strategy for PBGENE-HBV and plans to share safety data and Phase 1 trial details in November. It's important to note that these recent developments are part of the company's ongoing efforts to advance gene editing therapies.
InvestingPro Insights
Precision BioSciences' innovative ARCUS platform and its potential in gene editing are reflected in some of the company's financial metrics. According to InvestingPro data, Precision BioSciences has shown impressive revenue growth, with a 152.15% increase in quarterly revenue as of Q2 2024. This substantial growth aligns with the company's advancements in gene editing technology and its potential applications in various therapeutic areas.
Despite the promising technology, investors should note that the company is currently operating at a loss, with an adjusted operating income of -$7.29 million in the last twelve months. This is not uncommon for biotech companies in the development stage, as they often prioritize research and development over immediate profitability.
InvestingPro Tips highlight that Precision BioSciences holds more cash than debt on its balance sheet, which is crucial for a company investing heavily in cutting-edge technology. This financial cushion may provide the company with the necessary resources to continue its research and development efforts.
Another relevant InvestingPro Tip indicates that the stock is trading near its 52-week low. This could present an opportunity for investors who believe in the long-term potential of Precision BioSciences' ARCUS platform and its applications in gene editing therapies.
For those interested in a deeper analysis, InvestingPro offers 8 additional tips for Precision BioSciences, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.